Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.79 0.13 (0.53%) Market Cap: 3.07 Bil Enterprise Value: 2.91 Bil PE Ratio: 0 PB Ratio: 17.46 GF Score: 53/100

Arrowhead Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / NTS GMT
Release Date Price: €33.78 (+0.69%)
Maury Raycroft
Jefferies - Analyst

Hi, Everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'm happy to welcome our guests Vince Anzalone, Head of IR; and James Hamilton, Chief Discovery and Translational Medicine of Arrowhead. This is going to be a fireside chat format. So maybe to start off, if you guys want to provide a brief intro to Arrowhead.

Vince Anzalone
Arrowhead Pharmaceuticals, Inc. - IR

Sure. Thanks, Mark, and thanks to the whole Jefferies team for having us today. So, Arrowhead is an RNAi therapeutics platform company. So, we have a proprietary technology platform called TRiM or targeted RNA molecules. It allows us to induce target gene silencing across multiple tissue types, including liver, lung, muscle, CNS, and emerging adipose. Right now, we have 12 clinical stage candidates, 7 of those are wholly owned, 5 are partnered. And we have a 20 in '25 initiative, where we want to grow our pipeline of both clinical stage and marketed products to 20 by the year 2025.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot